Anteris Technologies Reports Decrease in Revenue and Increased Losses for Q2 2025

Anteris Technologies Global Corp. reported its financial results for the second quarter of 2025, revealing a net sales figure of $618,000, a slight decrease from $632,000 in the same period last year. For the first half of 2025, the company generated $1.2 million in revenue, down 16% from $1.4 million in the prior year. The decline in revenue is attributed to the expiration of a Transition Services Agreement with LeMaitre Vascular, which previously included sales of CardioCel™ and VascuCel™ products. However, this was partially offset by increased demand for other higher-yielding tissue products.

The company reported an operating loss of $20.9 million for the second quarter, compared to a loss of $18.5 million in the same quarter of 2024, marking a 13% increase in losses. For the first half of 2025, the operating loss was $42.7 million, an 18% increase from $36.3 million in the previous year. Research and development expenses rose significantly, totaling $16.3 million for the second quarter, up 29% year-over-year, primarily due to investments in manufacturing capabilities and preparatory activities for the upcoming PARADIGM Trial. Selling, general, and administrative expenses decreased by 19% to $5.0 million in the second quarter, reflecting reduced share-based payment expenses and lower marketing costs.

In terms of operational developments, Anteris is advancing its DurAVR® THV system, a single-piece heart valve designed for treating aortic stenosis. As of June 2025, 130 patients have been treated with the device globally. The company is preparing for the PARADIGM Trial, with 79 trial sites qualified across the U.S., Europe, and Canada. The trial aims to demonstrate the non-inferiority of the DurAVR® THV system compared to existing transcatheter aortic valve replacement (TAVR) systems. The company has submitted an investigational device exemption (IDE) to the FDA and anticipates enrollment to begin in the third quarter of 2025.

Anteris reported a cash balance of $28.4 million as of June 30, 2025, down from $70.5 million at the end of 2024. The company has indicated that it will require additional capital to fund ongoing operations and product development, particularly as it does not expect to generate significant revenue until after obtaining regulatory approvals for the DurAVR® THV system. The company has a history of raising capital through equity offerings and debt financing, but it acknowledges the uncertainty surrounding future funding efforts. The management has expressed confidence in its ability to secure necessary funds, although it recognizes the risks associated with market conditions and clinical outcomes.